Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG, designated in the United States as carbidopa‐levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the Unite...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mov Disord Clin Pract
Autors principals: Burack, Michelle, Aldred, Jason, Zadikoff, Cindy, Vanagunas, Arvydas, Klos, Kevin, Bilir, Bahri, Fernandez, Hubert H., Standaert, David G.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Reviews
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174493/
https://ncbi.nlm.nih.gov/pubmed/30363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12630
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars